IFM Therapeutics advances next-generation small-molecule immunotherapies that modulate novel targets in the innate immune system for cancer, auto-immunity, and inflammatory disorders. The company places each program or related set of programs into its own dedicated, independently financed R&D subsidiary supported by a common infrastructure and management team. IFM recently closed a $55.5M financing to fund near-term growth and program launches. The proceeds will be used to launch a third subsidiary, IFM Quattro, and a new incubator, IFM Discovery. IFM Quattro and IFM Discovery will focus on developing next-generation small-molecule immunotherapies for inflammatory diseases and cancers. IFM Discovery will work on a range of innate-immune targets, with the first target-specific program advancing into early preclinical development housed in the IFM Quattro subsidiary. IFM Therapeutics develops first-in-class small molecules that target proteins in the innate immune system. Its programs aim either to enhance innate immune responses for treating cancer or to dampen immune responses that drive inflammatory diseases. The company was seeded by Atlas Venture, was founded in 2015, and is based in Cambridge, Massachusetts. IFM will use the proceeds of the financing to advance and expand its early-stage portfolio and to begin clinical development of its most advanced product candidate, a selective activator of a novel target for treating solid tumors. The team is described as having deep expertise in medicinal chemistry and relevant biology and close ties to academic thought leaders. The company recently closed a financing that validates its early progress and plans for clinical advancement.

Total raised

$83M

Funding rounds

2

Latest round

Equity

Latest activity

Dec 2019